Astellas spotlights PFS, OS win for CLDN18.2 — six years after buying BioNTech founders' other company for $1.4B
Before Uğur Şahin and Özlem Türeci became known as the couple behind one of the world’s first Covid-19 vaccines — before they even founded BioNTech — they discovered a new pan-cancer target: isoform 2 of the tight junction molecule claudin-18, or CLDN18.2.
Ganymed, a German biotech they founded together, developed an antibody named zolbetuximab to go after that target and collected impressive mid-stage data in gastric cancer before Astellas came along in 2016 to buy out Ganymed in a $1.4 billion deal.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.